Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Zanetti SR"'
Autor:
Bueno, C, Barrena, S, Bataller, A, Ortiz-Maldonado, V, Elliott, N, O'Byrne, S, Wang, G, Rovira, M, Gutierrez-Agüera, F, Trincado, JL, Gonzalez, M, Morgades, M, Sorigué, M, Barcena, P, Zanetti, SR, Torrebadell, M, Vega-García, N, Rives, S, Mallo, M, Sole, F, Mead, AJ, Roberts, I, Thongjuea, S, Psaila, B, Juan, M, Delgado, J, Urbano-Ispizua, Á, Ribera, J-M, Orfao, A, Roy, A, Menéndez, P
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Web of Science
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Web of Science
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a4137a8616f5462683ece52e9a144ac
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6919
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6919
Autor:
Zanetti SR, Romecin PA, Vinyoles M, Manel Juan Otero, Fuster JL, Camós-Guijosa M, Querol S, Delgado M, Menendez P
Publikováno v:
Journal for ImmunoTherapy of Cancer
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
BACKGROUND: Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. Bone marrow (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::08cd06095a06b68a2a92409d38715316
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20097
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20097
Autor:
Velasco-Hernandez T, Zanetti SR, Roca-Ho H, Gutierrez-Aguera F, Petazzi P, Sánchez-Martínez D, Molina O, Baroni ML, Fuster JL, Ballerini P, Bueno C, Fernandez-Fuentes N, Engel P, Menendez P
Publikováno v:
Journal for ImmunoTherapy of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BACKGROUND: There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19(-) either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells repres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::305b18f33b5ff3b3589dcbb2be12f37f
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5051
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5051
Autor:
García-Del Río A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Prieto-Fernández E; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Egia-Mendikute L; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Antoñana-Vildosola A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Jimenez-Lasheras B; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Lee SY; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Barreira-Manrique A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Zanetti SR; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., de Blas A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Velasco-Beltrán P; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Bosch A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain., Aransay AM; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.; Genome Analysis Platform, CIC bioGUNE, Bizkaia Technology Park, Derio, Bizkaia, Spain., Palazon A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain.; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
Publikováno v:
JCI insight [JCI Insight] 2023 Oct 23; Vol. 8 (20). Date of Electronic Publication: 2023 Oct 23.
Autor:
Bueno C; Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; CIBER-ONC, ISCIII, Barcelona. cbueno@carrerasresearch.org., Martínez A; Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid., Romecin PA; Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid., Zanetti SR; Josep Carreras Leukemia Research Institute, Barcelona., Tirtakusuma R; Newcastle University, Newcastle upon Tyne., Genesca E; Josep Carreras Leukemia Research Institute, Barcelona., Camós M; Hematology Laboratory, Hospital Sant Joan de Déu. Barcelona. Spain; Leukemia and other pediatric hemopathies. Developmental tumor biology group. Instiutut de Recerca Hospital Sant Joan de Déu. Barcelona., Ramírez-Orellana M; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; Oncohematología. Hospital Niño Jesús. Madrid., Anguita E; Servicio de Hematología. Hospital Clínico San Carlos. IdISSC, Medicina UCM. Madrid., Ballerini P; Pediatric Hematology. Armand Trosseau Hospital. Paris., Locatelli F; Department of Hematology and Oncology. Ospedale Bambino Gesú. Rome., Fuster JL; Sección de Oncohematología Pediátrica, Hospital Clínico Universitario Virgen de la Arrixaca and Instituto Murciano de Investigación Biosanitaria (IMIB), El Palmar, Murcia., Menéndez P; Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; CIBER-ONC, ISCIII, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona. pmenendez@carrerasresearch.org.
Publikováno v:
Haematologica [Haematologica] 2023 Aug 01; Vol. 108 (8), pp. 2229-2233. Date of Electronic Publication: 2023 Aug 01.
Autor:
Egia-Mendikute L; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Bosch A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Prieto-Fernández E; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Vila-Vecilla L; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Zanetti SR; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Lee SY; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Jiménez-Lasheras B; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., García Del Río A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Antoñana-Vildosola A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., de Blas A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Velasco-Beltrán P; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Serrano-Maciá M; Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Iruzubieta P; Servicio Inmunología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Cantabria, Spain., Mehrpouyan M; BD Biosciences, San Jose, CA, United States., Goldberg EM; BD Biosciences, San Jose, CA, United States., Bornheimer SJ; BD Biosciences, San Jose, CA, United States., Embade N; Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain., Martínez-Chantar ML; Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., López-Hoyos M; Servicio Inmunología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Cantabria, Spain., Mato JM; Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Millet Ó; Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Palazón A; Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.; Ikerbasque, Basque Foundation for Science, Bizkaia, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Nov 24; Vol. 13, pp. 1014309. Date of Electronic Publication: 2022 Nov 24 (Print Publication: 2022).
Autor:
Bueno C; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Barrera S; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., Bataller A; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain.; Department of Clinical Hematology, Hospital Clinic of Barcelona, Barcelona, Spain., Ortiz-Maldonado V; Department of Clinical Hematology, Hospital Clinic of Barcelona, Barcelona, Spain., Elliot N; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital., O'Byrne S; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital., Wang G; MRC (Medical Research Council) Molecular Haematology Unit, and.; Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford, United Kingdom., Rovira M; Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford, United Kingdom., Gutierrez-Agüera F; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain., Trincado JL; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., González-González M; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., Morgades M; Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Spain., Sorigué M; Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Spain.; Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain., Bárcena P; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., Zanetti SR; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain., Torrebadell M; Haematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.; Developmental Tumor Biology Group, Leukemia and Other Pediatric Hemopathies, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain., Vega-Garcia N; Haematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.; Developmental Tumor Biology Group, Leukemia and Other Pediatric Hemopathies, Institut de Recerca Sant Joan de Déu, Barcelona, Spain., Rives S; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.; Department of Clinical Hematology, Hospital Sant Joan de Déu, Barcelona, Spain., Mallo M; Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain., Sole F; Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain., Mead AJ; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain., Roberts I; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital.; MRC (Medical Research Council) Molecular Haematology Unit, and.; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Thongjuea S; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital.; MRC (Medical Research Council) Molecular Haematology Unit, and.; Department of Clinical Hematology, Hospital Sant Joan de Déu, Barcelona, Spain., Psaila B; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital.; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Juan M; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain., Delgado J; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Department of Clinical Hematology, Hospital Clinic of Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Urbano-Ispizúa A; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Department of Clinical Hematology, Hospital Clinic of Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Ribera JM; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Spain.; Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain., Orfao A; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., Roy A; Department of Paediatrics, Children's Hospital, John Radcliffe Hospital.; MRC (Medical Research Council) Molecular Haematology Unit, and.; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Menendez P; Josep Carreras Leukemia Research Institute, Campus Clinic, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC) and.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0029), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; and.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Publikováno v:
Blood [Blood] 2022 Jul 07; Vol. 140 (1), pp. 38-44.
Autor:
Blanco B; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain.; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (RICORS, RD21/0017/0029), Madrid, Spain., Ramírez-Fernández Á; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Bueno C; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (RICORS, RD21/0017/0029), Madrid, Spain.; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Argemí-Muntadas L; Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus, Denmark., Fuentes P; Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain., Aguilar-Sopeña Ó; Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain.; Lymphocyte Immunobiology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Gutierrez-Agüera F; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (RICORS, RD21/0017/0029), Madrid, Spain.; Josep Carreras Leukemia Research Institute, Barcelona, Spain., Zanetti SR; Josep Carreras Leukemia Research Institute, Barcelona, Spain., Tapia-Galisteo A; Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain., Díez-Alonso L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Segura-Tudela A; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Castellà M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain., Marzal B; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain., Betriu S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain., Harwood SL; Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus, Denmark., Compte M; Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain., Lykkemark S; Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus, Denmark., Erce-Llamazares A; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Rubio-Pérez L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain.; Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain., Jiménez-Reinoso A; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Domínguez-Alonso C; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Neves M; Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain., Morales P; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain., Paz-Artal E; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain., Guedan S; Department of Hematology and Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain., Sanz L; Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain., Toribio ML; Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain., Roda-Navarro P; Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain.; Lymphocyte Immunobiology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain., Juan M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.; Servei d'Immunologia, Hospital Clínic de Barcelona, Barcelona, Spain.; Plataforma Immunoteràpia Hospital Sant Joan de Déu, Barcelona, Spain.; Universitat de Barcelona, Barcelona, Spain., Menéndez P; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (RICORS, RD21/0017/0029), Madrid, Spain.; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Álvarez-Vallina L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain.; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (RICORS, RD21/0017/0029), Madrid, Spain.; Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus, Denmark.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2022 Apr 01; Vol. 10 (4), pp. 498-511.
Autor:
Zanetti SR; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain. Electronic address: samzanetti@gmail.com., Velasco-Hernandez T; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain. Electronic address: tvelasco@carrerasresearch.org., Gutierrez-Agüera F; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain., Díaz VM; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; OneChain Immunotherapeutics S.L., Barcelona, Spain; Faculty of Medicine and Health Sciences, International University of Catalonia, Sant Cugat del Vallès 08195, Spain., Romecín PA; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain., Roca-Ho H; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain., Sánchez-Martínez D; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain., Tirado N; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain., Baroni ML; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain., Petazzi P; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain., Torres-Ruiz R; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain., Molina O; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain., Bataller A; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; Department of Hematology, Hospital Clínic de Barcelona, Barcelona 08036, Spain., Fuster JL; RICORS-TERAV, ISCIII, Madrid, Spain; Sección de Oncohematología Pediátrica, Hospital Virgen de Arrixaca, Murcia 30120, Spain., Ballerini P; Department of Pediatric Hemato-oncology, Hospital Armand Trousseau, Paris 75012, France., Juan M; RICORS-TERAV, ISCIII, Madrid, Spain; Department of Immunology, Hospital Clínic de Barcelona and Hospital Sant Joan de Déu, Barcelona 08950, Spain., Jeremias I; Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, German Center for Environmental Health (HMGU), Munich 85764, Germany; Department of Pediatrics, Dr von Hauner Children's Hospital, LMU, Munich 80337, Germany., Bueno C; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain; CIBER-ONC, ISCIII, Barcelona, Spain., Menéndez P; Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Carrer Casanova 143, 4° floor, Barcelona 08036, Spain; RICORS-TERAV, ISCIII, Madrid, Spain; CIBER-ONC, ISCIII, Barcelona, Spain; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona 08036, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Electronic address: pmenendez@carrerasresearch.org.
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2022 Feb 02; Vol. 30 (2), pp. 550-563. Date of Electronic Publication: 2021 Sep 01.
Autor:
Antoñana-Vildosola A; Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain., Zanetti SR; Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain., Palazon A; Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain; Ikerbasque, Basque Foundation for Science, Bizkaia, Spain. Electronic address: apalazon@cicbiogune.es.
Publikováno v:
International review of cell and molecular biology [Int Rev Cell Mol Biol] 2022; Vol. 370, pp. 123-147. Date of Electronic Publication: 2022 May 23.